{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:31:55Z","timestamp":1791217915373,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,5,20]],"date-time":"2008-05-20T00:00:00Z","timestamp":1211241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/ncpneuro0810","type":"journal-article","created":{"date-parts":[[2008,5,20]],"date-time":"2008-05-20T12:37:25Z","timestamp":1211287045000},"page":"317-327","source":"Crossref","is-referenced-by-count":93,"title":["Steroids and immunosuppressant drugs in myasthenia gravis"],"prefix":"10.1038","volume":"4","author":[{"given":"Sivakumar","family":"Sathasivam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,20]]},"reference":[{"key":"BFncpneuro0810_CR1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"DB Drachman","year":"1994","unstructured":"Drachman DB (1994) Myasthenia gravis. N Engl J Med 330: 1797\u20131810","journal-title":"N Engl J Med"},{"key":"BFncpneuro0810_CR2","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent A and Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis. J Neurol Neurosurg Psychiatry 48: 1246\u20131252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0810_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.20854","volume":"36","author":"KH Chan","year":"2007","unstructured":"Chan KH  et al. (2007) Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 36: 651\u2013658","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0810_CR4","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM  et al. (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843\u20132854","journal-title":"J Clin Invest"},{"key":"BFncpneuro0810_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pharmthera.2006.03.005","volume":"112","author":"MC Dalakas","year":"2006","unstructured":"Dalakas MC (2006) B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 112: 57\u201370","journal-title":"Pharmacol Ther"},{"key":"BFncpneuro0810_CR6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A  et al. (2001) Myasthenia gravis. Lancet 357: 2122\u20132128","journal-title":"Lancet"},{"key":"BFncpneuro0810_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","volume":"377","author":"D Grob","year":"1981","unstructured":"Grob D  et al. (1981) The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 377: 652\u2013669","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1749-6632.1981.tb33766.x","volume":"377","author":"HJ Oosterhuis","year":"1981","unstructured":"Oosterhuis HJ (1981) Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann NY Acad Sci 377: 678\u2013690","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR9","first-page":"75","volume":"25","author":"HJ Oosterhuis","year":"1988","unstructured":"Oosterhuis HJ (1988) Long-term effects of treatment in 374 patients with myasthenia gravis. Monogr Allergy 25: 75\u201385","journal-title":"Monogr Allergy"},{"key":"BFncpneuro0810_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","volume":"56","author":"AL Taylor","year":"2005","unstructured":"Taylor AL  et al. (2005) Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 56: 23\u201346","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFncpneuro0810_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0162-3109(00)00186-7","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC (2000) Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47: 63\u201383","journal-title":"Immunopharmacology"},{"key":"BFncpneuro0810_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1183\/09031936.98.12010221","volume":"12","author":"PJ Barnes","year":"1998","unstructured":"Barnes PJ and Adcock IM (1998) Transcription factors and asthma. Eur Respir J 12: 221\u2013234","journal-title":"Eur Respir J"},{"key":"BFncpneuro0810_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD (2006) Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 6: 859\u2013866","journal-title":"Am J Transplant"},{"key":"BFncpneuro0810_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1749-6632.1976.tb47724.x","volume":"274","author":"G Matell","year":"1976","unstructured":"Matell G  et al. (1976) Effects of some immunosuppressive procedures in myasthenia gravis. Ann NY Acad Sci 274: 659\u2013676","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","volume":"377","author":"HG Mertens","year":"1981","unstructured":"Mertens HG  et al. (1981) Effect of immunosuppressive drugs (azathioprine). Ann NY Acad Sci 377: 691\u2013698","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ana.410150615","volume":"15","author":"AS Witte","year":"1984","unstructured":"Witte AS  et al. (1984) Azathioprine in the treatment of myasthenia gravis. Ann Neurol 15: 602\u2013605","journal-title":"Ann Neurol"},{"key":"BFncpneuro0810_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0960-8966(91)90005-D","volume":"1","author":"JBM Kuks","year":"1991","unstructured":"Kuks JBM  et al. (1991) Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul Disord 1: 423\u2013431","journal-title":"Neuromuscul Disord"},{"key":"BFncpneuro0810_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00314245","volume":"235","author":"R Mantegazza","year":"1988","unstructured":"Mantegazza R  et al. (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 235: 449\u2013453","journal-title":"J Neurol"},{"key":"BFncpneuro0810_CR19","first-page":"765","volume":"91","author":"JM Heckmann","year":"2001","unstructured":"Heckmann JM  et al. (2001) High-dose immunosuppressive therapy in generalised myasthenia gravis\u2014a 2-year follow-up study. S Afr Med J 91: 765\u2013770","journal-title":"S Afr Med J"},{"key":"BFncpneuro0810_CR20","doi-asserted-by":"crossref","unstructured":"Myasthenia Gravis Clinical Study Group (1993) A randomised clinical trial comparing prednisolone and azathioprine in myasthenia gravis. Results of a second interim analysis. J Neurol Neurosurg Psychiatry 56: 1157\u20131163","DOI":"10.1136\/jnnp.56.11.1157"},{"key":"BFncpneuro0810_CR21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J  et al. (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50: 1778\u20131783","journal-title":"Neurology"},{"issue":"Suppl","key":"BFncpneuro0810_CR22","first-page":"165","volume":"37","author":"BCG Schalke","year":"1990","unstructured":"Schalke BCG  et al. (1990) Immunosuppressive treatment of myasthenia gravis. Results of a double-blind trial\u2014ciclosporin A (CSA) versus azathioprine (AZA). Jikeikai Med J 37 (Suppl): 165\u2013169","journal-title":"Jikeikai Med J"},{"key":"BFncpneuro0810_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","volume":"150","author":"MB Bromberg","year":"1997","unstructured":"Bromberg MB  et al. (1997) Randomized trial of azathioprine or prednisolone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 150: 59\u201362","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0810_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.31.1.32","volume":"31","author":"MC Perez","year":"1981","unstructured":"Perez MC  et al. (1981) Stable remissions in myasthenia gravis. Neurology 31: 32\u201337","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.10133","volume":"26","author":"LG De Feo","year":"2002","unstructured":"De Feo LG  et al. (2002) Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 26: 31\u201336","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0810_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","volume":"13","author":"GO Skeie","year":"2006","unstructured":"Skeie GO  et al. (2006) Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 13: 691\u2013699","journal-title":"Eur J Neurol"},{"issue":"Suppl 3","key":"BFncpneuro0810_CR27","first-page":"A137","volume":"54","author":"L Cos","year":"2000","unstructured":"Cos L  et al. (2000) Mycophenolate mofetil (MyM) is safe and well tolerated in myasthenia gravis (MG). Neurology 54 (Suppl 3): A137","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1212\/WNL.56.1.97","volume":"56","author":"E Ciafaloni","year":"2001","unstructured":"Ciafaloni E  et al. (2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56: 97\u201399","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.56.1.94","volume":"56","author":"V Chaudhry","year":"2001","unstructured":"Chaudhry V  et al. (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56: 94\u201396","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR30","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","volume":"61","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN  et al. (2003) Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61: 1438\u20131440","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1196\/annals.1254.064","volume":"998","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN  et al. (2003) Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 998: 494\u2013499","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR32","unstructured":"Aspreva Pharmaceuticals Corporation [\n                    http:\/\/www.aspreva.com\n                    \n                  ]"},{"issue":"3 Suppl 4","key":"BFncpneuro0810_CR33","first-page":"211","volume":"20","author":"M Goulon","year":"1988","unstructured":"Goulon M  et al. (1988) Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis. Transplant Proc 20 (3 Suppl 4): 211\u2013217","journal-title":"Transplant Proc"},{"key":"BFncpneuro0810_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s004150050141","volume":"244","author":"DM Bonifati","year":"1997","unstructured":"Bonifati DM and Angelini C (1997) Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 244: 542\u2013547","journal-title":"J Neurol"},{"key":"BFncpneuro0810_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","volume":"111","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D  et al. (2005) Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 111: 247\u2013252","journal-title":"Acta Neurol Scand"},{"key":"BFncpneuro0810_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RSA Tindall","year":"1987","unstructured":"Tindall RSA  et al. (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316: 719\u2013724","journal-title":"N Engl J Med"},{"key":"BFncpneuro0810_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RS Tindall","year":"1993","unstructured":"Tindall RS  et al. (1993) A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 681: 539\u2013551","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR38","volume-title":"Cochrane Database of Systematic Reviews","author":"IK Hart","year":"2007","unstructured":"Hart IK  et al. (2007) Immunosuppressive agents for myasthenia gravis. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005224. doi:10.1002\/14651858.CD005224.pub2"},{"key":"BFncpneuro0810_CR39","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.10472","volume":"28","author":"T Konishi","year":"2003","unstructured":"Konishi T  et al. (2003) Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 28: 570\u2013574","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0810_CR40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","volume":"76","author":"T Konishi","year":"2005","unstructured":"Konishi T  et al. (2005) Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 76: 448\u2013450","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0810_CR41","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1185\/030079904125004385","volume":"20","author":"N Kawaguchi","year":"2004","unstructured":"Kawaguchi N  et al. (2004) Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20: 1269\u20131273","journal-title":"Curr Med Res Opin"},{"key":"BFncpneuro0810_CR42","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","volume":"64","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM  et al. (2005) Long-term results of tacrolimus in cyclosporine- and prednisolone-dependent myasthenia gravis. Neurology 64: 1641\u20131643","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR43","doi-asserted-by":"crossref","unstructured":"Ponseti JM  et al. (2007) Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci [doi:10.1196\/annals.1405.000]","DOI":"10.1196\/annals.1405.000"},{"key":"BFncpneuro0810_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000085833","volume":"53","author":"Y Nagane","year":"2005","unstructured":"Nagane Y  et al. (2005) Efficacy of low-dose FK506 in the treatment of myasthenia gravis\u2014a randomized pilot study. Eur Neurol 53: 146\u2013150","journal-title":"Eur Neurol"},{"key":"BFncpneuro0810_CR45","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1001\/jama.1935.02760230013004","volume":"104","author":"HE Simon","year":"1935","unstructured":"Simon HE (1935) Myasthenia gravis: effect of treatment with anterior pituitary extract. JAMA 104: 2065\u20132066","journal-title":"JAMA"},{"key":"BFncpneuro0810_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1749-6632.1971.tb30766.x","volume":"183","author":"G Genkins","year":"1971","unstructured":"Genkins G  et al. (1971) The use of ACTH and corticosteroids in myasthenia gravis. Ann NY Acad Sci 183: 369\u2013374","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/WNL.22.6.603","volume":"22","author":"NG Brunner","year":"1972","unstructured":"Brunner NG  et al. (1972) Corticosteroids in the management of severe generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. Neurology 22: 603\u2013610","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR48","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","volume":"42","author":"EL Arsura","year":"1985","unstructured":"Arsura EL  et al. (1985) High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 42: 1149\u20131153","journal-title":"Arch Neurol"},{"key":"BFncpneuro0810_CR49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM  et al. (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15: 291\u2013298","journal-title":"Ann Neurol"},{"key":"BFncpneuro0810_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/WNL.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A  et al. (1984) Myasthenia gravis: prolonged treatment with steroids. Neurology 34: 170\u2013174","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","volume":"84","author":"V Cosi","year":"1991","unstructured":"Cosi V  et al. (1991) Effectiveness of steroid treatment in myasthenia gravis: a retrospective study. Acta Neurol Scand 84: 33\u201339","journal-title":"Acta Neurol Scand"},{"key":"BFncpneuro0810_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000116785","volume":"32","author":"A Evoli","year":"1992","unstructured":"Evoli A  et al. (1992) Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 32: 37\u201343","journal-title":"Eur Neurol"},{"key":"BFncpneuro0810_CR53","first-page":"28","volume":"33","author":"B Bu","year":"2000","unstructured":"Bu B  et al. (2000) A prospective study of effectiveness and safety of long-term prednisone therapy in patients with myasthenia gravis [Chinese]. Zhonghua Shen Jing Ge Za Zhi 33: 28\u201331","journal-title":"Zhonghua Shen Jing Ge Za Zhi"},{"key":"BFncpneuro0810_CR54","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","volume":"274","author":"FM Howard Jr","year":"1976","unstructured":"Howard FM Jr  et al. (1976) Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann NY Acad Sci 274: 596\u2013607","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0810_CR55","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C  et al. (1998) Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 97: 370\u2013373","journal-title":"Acta Neurol Scand"},{"key":"BFncpneuro0810_CR56","first-page":"612","volume":"36","author":"J Zhang","year":"1998","unstructured":"Zhang J  et al. (1998). Effectiveness of steroid treatment in juvenile myasthenia gravis [Chinese]. Zhonghua Er Ke Za Zhi 36: 612\u2013614","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"BFncpneuro0810_CR57","first-page":"412","volume":"21","author":"JR Warmolts","year":"1971","unstructured":"Warmolts JR and Engel WK (1971) Benefit from alternate-day prednisone in myasthenis gravis. Neurology 21: 412\u2013417","journal-title":"Neurology"},{"key":"BFncpneuro0810_CR58","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","volume":"254","author":"M Thakre","year":"2007","unstructured":"Thakre M  et al. (2007) Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 254: 968\u2013969","journal-title":"J Neurol"},{"key":"BFncpneuro0810_CR59","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","volume":"78","author":"WS Baek","year":"2007","unstructured":"Baek WS  et al. (2007) Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 78: 771","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Nature Clinical Practice Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0810","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:33:13Z","timestamp":1684441993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneuro0810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,20]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BFncpneuro0810"],"URL":"https:\/\/doi.org\/10.1038\/ncpneuro0810","relation":{},"ISSN":["1745-834X","1745-8358"],"issn-type":[{"value":"1745-834X","type":"print"},{"value":"1745-8358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,20]]}}}